Patents by Inventor Mark A. Paulik

Mark A. Paulik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20240239861
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: October 19, 2023
    Publication date: July 18, 2024
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Glucagon-receptor selective polypeptides and methods of use thereof
    Patent number: 11840559
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: December 12, 2023
    Assignee: i2o Therapeutics, Inc.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20220332781
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: November 30, 2021
    Publication date: October 20, 2022
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Glucagon-receptor selective polypeptides and methods of use thereof
    Patent number: 11214607
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 4, 2022
    Assignee: Intarcia Therapeutics Inc.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20200299350
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: October 29, 2019
    Publication date: September 24, 2020
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Glucagon-receptor selective polypeptides and methods of use thereof
    Patent number: 10501517
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 10, 2019
    Assignee: INTARCIA THERAPEUTICS, INC.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20180009871
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: May 15, 2017
    Publication date: January 11, 2018
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young